Payment overview · 2025
General Payments
$95.01
5 reported records · 3 companies
Healthcare provider profile · identity verified
Douglas Olson, MD
Allopathic & Osteopathic Physicians|Family Medicine · WATERTOWN, SD · NPI 1780875641
Verified facts
What the public records show
CMS Open Payments records show Douglas Olson, MD received $95.01 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.55 | 53.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.63 | 30.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.83 | 16.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.01 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.55 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 763 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 410 | 99 |
| Omeprazole | Omeprazole | 406 | 93 |
| Lisinopril | Lisinopril | 345 | 89 |
| Furosemide | Furosemide | 320 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 318 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 77 |
| Losartan Potassium | Losartan Potassium | 303 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 297 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 79 |
| Gabapentin | Gabapentin | 281 | 60 |
| Simvastatin | Simvastatin | 280 | 66 |
| Warfarin Sodium | Warfarin Sodium | 204 | 26 |
| Allopurinol | Allopurinol | 185 | 47 |
| Potassium Chloride | Potassium Chloride | 166 | 41 |
| Metformin Hcl | Metformin Hcl | 162 | 43 |
| Tramadol Hcl | Tramadol Hcl | 162 | 38 |
| Carvedilol | Carvedilol | 155 | 43 |
| Glipizide Er | Glipizide | 152 | 35 |
| Finasteride | Finasteride | 139 | 35 |
| Metformin Hcl Er | Metformin Hcl | 135 | 33 |
| Xarelto | Rivaroxaban | 134 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 28 |
| Eliquis | Apixaban | 120 | 31 |
| Bupropion Xl | Bupropion Hcl | 119 | 25 |
| Prednisone | Prednisone | 118 | 49 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 115 | 20 |
| Donepezil Hcl | Donepezil Hcl | 110 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 26 |
| Memantine Hcl | Memantine Hcl | 92 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 17 |
| Fentanyl | Fentanyl | 89 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 86 | 22 |
| Fenofibrate | Fenofibrate | 80 | 12 |
| Alprazolam | Alprazolam | 77 | 17 |
| Mounjaro | Tirzepatide | 75 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 12 |
| Farxiga | Dapagliflozin Propanediol | 72 | 14 |
| Montelukast Sodium | Montelukast Sodium | 72 | 17 |
| Terazosin Hcl | Terazosin Hcl | 72 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 18 |
| Ezetimibe | Ezetimibe | 64 | 19 |
| Famotidine | Famotidine | 64 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 26 |
| Myrbetriq | Mirabegron | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Olanzapine | Olanzapine | 57 | suppressed |
| Lorazepam | Lorazepam | 56 | 16 |
| Primidone | Primidone | 56 | 12 |
| Alendronate Sodium | Alendronate Sodium | 54 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 21 |
| Spironolactone | Spironolactone | 52 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Digoxin | Digoxin | 51 | 14 |
| Glimepiride | Glimepiride | 50 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 11 |
| Atenolol | Atenolol | 43 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 33 |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 14 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 23 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Jantoven | Warfarin Sodium | 29 | suppressed |
| Nystatin | Nystatin | 29 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Etodolac | Etodolac | 27 | 18 |
| Lactulose | Lactulose | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 12 |
| Celecoxib | Celecoxib | 26 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Glipizide | Glipizide | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | 11 |
| Nitroglycerin | Nitroglycerin | 18 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Budesonide | Budesonide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Drospirenone-Ethinyl Estradiol | Ethinyl Estradiol/Drospirenone | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.01 · 5 records | Amgen Inc. | CAMZYOS, EVENITY, QULIPTA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error